DUBLIN--(BUSINESS WIRE)--The "Global Hepatitis B Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The global hepatitis B therapeutics market is fragmented, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development.
These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.
Increasing prevalence of hepatitis B in infants
The increase in the prevalence of hepatitis B in infants, the companies are developing various drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.
Low accessibility due to high cost of hepatitis B treatment
One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.
Key Players
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Gilead
- GlaxoSmithKline
- Merck Sharp & Dohme
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY APPLICATION
- Segmentation by application
- Comparison by application
- Drugs - Market size and forecast 2017-2022
- Vaccines - Market size and forecast 2017-2022
- Market opportunity by application
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
PART 13: MARKET TRENDS
- Strategic alliances
- Strong pipeline
- New technological advancements
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Gilead
- GlaxoSmithKline
-
Merck Sharp & Dohme
For more information about this report visit https://www.researchandmarkets.com/research/dcgndb/global_hepatitis?w=4
